Faron Pharmaceuticals
Ltd.
("Faron"
or the "Company")
Faron
Pharmaceuticals
Notice of Half-Year Financial
Results
Company
Announcement, 20 August 2024
TURKU, Finland - Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a
clinical-stage biopharmaceutical company pursuing a CLEVER approach
to reprogramming myeloid cells to activate anti-tumor immunity in
hematological and solid tumor microenvironments,
will report its unaudited half-year financial
results for the six months ended June 30, 2024, on Tuesday, 27
August 2024.
A live hybrid briefing and Q&A
session for investors, analysts and media will be hosted by Dr.
Juho Jalkanen, Chief Executive Officer, and Yrjö Wichmann, Chief Financial Officer, at 08:00 am (EDT) /
13:00 pm (BST) / 15:00 pm (EEST) on Wednesday, 28 August
2024.
Webcast registration link:
https://faron.videosync.fi/q2-2024
Live participation
In addition to the webcast, there
are a number of spaces available to attend the briefing in-person
at Studio Eliel in Sanomatalo at Töölönlahdenkatu 2, Helsinki. To
register, please contact
investor.relations@faron.com
no later than 10:00 a.m. EEST on Monday, 26 August
2024. Please note that places are limited, and you will receive a
separate email confirmation.
The half-year report, presentation,
and a replay of the webcast will be available on the Company's
website at www.faron.com/investors.
For
more information please contact:
Investor Contact
Faron Pharmaceuticals
E-mail: investor.relations@faron.com
Media Contact
ICR Consilium
Mary-Jane Elliott, David Daley,
Lindsey Neville
Phone: +44 (0)20 3709 5700
E-mail: faron@consilium-comms.com
Cairn Financial Advisers LLP,
Nomad
Sandy Jamieson, Jo Turner
Phone: +44 (0) 207 213
0880
Peel Hunt LLP, Broker
Christopher Golden, James
Steel
Phone: +44 (0) 20 7418
8900
Sisu Partners Oy, Certified Adviser
on Nasdaq First North
Juha Karttunen
Phone: +358 (0)40 555 4727
Jukka Järvelä
Phone: +358 (0)50 553 8990
About BEXMAB
The BEXMAB study is an open-label
Phase 1/2 clinical trial investigating bexmarilimab in combination with
standard of care (SoC) in the aggressive hematological malignancies
of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
The primary objective is to determine the safety and tolerability
of bexmarilimab in combination with SoC (azacitidine) treatment.
Directly targeting Clever-1 could limit the replication capacity of
cancer cells, increase antigen presentation, ignite an immune
response, and allow current treatments to be more effective.
Clever-1 is highly expressed in both AML and MDS and associated
with therapy resistance, limited T cell activation and poor
outcomes.
About Bexmarilimab
Bexmarilimab is Faron's wholly owned,
investigational immunotherapy designed to overcome resistance to
existing treatments and optimize clinical outcomes, by targeting
myeloid cell function and igniting the immune
system. Bexmarilimab binds to Clever-1,
an immunosuppressive receptor found on macrophages leading to tumor
growth and metastases (i.e. helps cancer evade the immune system).
By targeting the Clever-1 receptor on
macrophages, bexmarilimab alters
the tumor microenvironment, reprogramming macrophages from an
immunosuppressive (M2) state to an immunostimulatory (M1) one,
upregulating interferon production and priming the immune system to
attack tumors and sensitizing cancer cells to standard of
care.
About Faron Pharmaceuticals
Ltd.
Faron (AIM: FARN, First North:
FARON) is a global, clinical-stage biopharmaceutical company,
focused on tackling cancers via novel immunotherapies. Its mission
is to bring the promise of immunotherapy to a broader population by
uncovering novel ways to control and harness the power of the
immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1
humanized antibody, with the potential to remove immunosuppression
of cancers through reprogramming myeloid cell
function. Bexmarilimab is being
investigated in Phase I/II clinical trials as a potential therapy
for patients with hematological cancers in combination with other
standard treatments. Further information is available
at www.faron.com.
Forward-Looking Statements
Certain statements in this
announcement are, or may be deemed to be, forward-looking
statements. Forward looking statements are identified by their use
of terms and phrases such as ''believe'', ''could'', "should",
"expect", "hope", "seek", ''envisage'', ''estimate'', ''intend'',
''may'', ''plan'', ''potentially'', ''will'' or the negative of
those, variations or comparable expressions, including references
to assumptions. These forward-looking statements are not based on
historical facts but rather on the Directors' current expectations
and assumptions regarding the Company's future growth, results of
operations, performance, future capital and other expenditures
(including the amount, nature and sources of funding thereof),
competitive advantages, business prospects and opportunities. Such
forward-looking statements reflect the Directors' current beliefs
and assumptions and are based on information currently available to
the Directors.
A number of factors could cause
actual results to differ materially from the results and
expectations discussed in the forward-looking statements, many of
which are beyond the control of the Company. In addition, other
factors which could cause actual results to differ materially
include the ability of the Company to successfully license its
programs within the anticipated timeframe or at all, risks
associated with vulnerability to general economic and business
conditions, competition, environmental and other regulatory
changes, actions by governmental authorities, the availability of
capital markets or other sources of funding, reliance on key
personnel, uninsured and underinsured losses and other factors.
Although any forward-looking statements contained in this
announcement are based upon what the Directors believe to be
reasonable assumptions, the Company cannot assure investors that
actual results will be consistent with such forward-looking
statements. Accordingly, readers are cautioned not to place undue
reliance on forward-looking statements. Subject to any continuing
obligations under applicable law or any relevant AIM Rule
requirements, in providing this information the Company does not
undertake any obligation to publicly update or revise any of the
forward-looking statements or to advise of any change in events,
conditions or circumstances on which any such statement is
based.